Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.45M
Average 0.26M
PBYI Purchases of Investments
Cash used to buy marketable securities and other investments.
Puma Biotechnology, Inc.NASDAQ: PBYI
Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026
Purchases of investments growth accelerates
Q1 FY2026 purchases of investments of $24.86M (cash outflow) rose 98.8% year over year, ahead of the +89.0% change in trailing-twelve-month purchases of investments. Sequentially, it fell 47.0% from the prior quarter. Over 3 fiscal years it compounded at +181.7% a year.
Context
- Purchases of investments amounted to 47.4% of revenue in FY2025, up 14.3 pp from a year earlier.
- Purchases of investments grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +98.8% holds above the trailing-twelve-month pace of +89.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (108.14M) USD
- Year-over-year change
- -41.9%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (108.14M) | -41.9% |
| FY2024 | 2024-12-31 | (76.23M) | -220.1% |
| FY2023 | 2023-12-31 | (23.81M) | -392.4% |
| FY2022 | 2022-12-31 | (4.84M) | +87.3% |
| FY2021 | 2021-12-31 | (38.07M) | — |
Purchases of Investments vs competitors
How PBYI compares with its peers on the latest reported figures
- Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +89.0% is the 4th highest of 8, against a peer median of +60.6%.
- Purchases of investments amounts to 53.0% of revenue for PBYI, versus a peer median of 80.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.05B USD | +760.8% | +8.2% | — | |
| LTM Mar 2026 | $413.13M USD | +104.3% | +18.9% | — | |
| LTM Mar 2026 | $327.5M USD | +60.6% | — | — | |
| LTM Mar 2026 | $202.4M USD | +485.0% | +20.0% | 128.9% | |
| LTM Mar 2026 | $140.56M USD | +49.4% | +39.7% | — | |
| LTM Mar 2026 | $120.5M USD | +89.0% | +181.7% | 53.0% | |
| LTM Mar 2026 | $47.87M USD | -16.8% | -8.0% | 9118.7% | |
| LTM Mar 2026 | $16.02M USD | — | — | 32.3% | |
| LTM Jun 2026 | $7.46M USD | -97.1% | -12.0% | 4.4% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥171.53K CNY | — | -81.1% | — |
| LTM Mar 2026 | CA$0 CAD | — | — | — | |
| Peer median (excluding PBYI) | — | +60.6% | +8.2% | 80.6% | |
Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (29.13M) | 2K | 21.59M | 30.28M | 31.11M |
| Depreciation & Amortization | 11.31M | 9.84M | 11.52M | 11.52M | 10.94M |
| Deferred Income Tax | 0 | 0 | 0 | (7.08M) | 3.25M |
| Stock-Based Compensation | 32.63M | 11.83M | 10.25M | 8.25M | 6.94M |
| Change in Working Capital | (1.31M) | (44.5M) | (17.85M) | (3.54M) | (10.08M) |
| Accounts Receivables | (5.98M) | (7.82M) | (8.37M) | 16.35M | (21.28M) |
| Inventory | (3.66M) | 2.58M | (2.55M) | (1.64M) | 3.21M |
| Accounts Payables | (902K) | (4.73M) | 449K | (1.38M) | (453K) |
| Other Working Capital | 9.23M | (34.52M) | (7.38M) | (16.86M) | 8.45M |
| Other Non-Cash Items | 7.15M | 7M | 1.51M | (519K) | (358K) |
| Operating Cash Flow | 20.65M | (15.83M) | 27.01M | 38.92M | 41.8M |
| Capital Expenditures | 0 | (7M) | (12.64M) | (56K) | (71K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (38.07M) | (4.84M) | (23.81M) | (76.23M) | (108.14M) |
| Sales of Investments | 27.19M | 18.94M | 17.33M | 55.85M | 72.02M |
| Other Investing Activities | 0 | 0 | (12.5M) | 0 | 0 |
| Investing Cash Flow | (10.88M) | 7.1M | (19.13M) | (20.44M) | (36.19M) |
| Debt Repayment | (1.5M) | 0 | 0 | (33.33M) | (44.44M) |
| Common Stock Issued | 0 | 12.5M | 0 | 150K | 130K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (30.43M) | (277K) | 0 | (666K) | (888K) |
| Financing Cash Flow | (31.93M) | 12.22M | 0 | (33.85M) | (45.2M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (22.16M) | 3.5M | 7.88M | (15.37M) | (39.58M) |
| Free Cash Flow | 20.65M | (22.83M) | 14.37M | 38.86M | 41.73M |
Puma Biotechnology, Inc.
NASDAQ:PBYI
Intrinsic Alpha fair value
Locked
Current Price
$7.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.